Cardiovascular Outcomes of Sitagliptin in Type 2 Diabetic Patients with Acute Myocardial Infarction, a Population-Based Cohort Study in Taiwan

BACKGROUND: The cardiovascular safety and efficacy of sitagliptin, a dipeptidyl peptidase 4 (DPP-4) inhibitor, in type 2 diabetic patients after acute myocardial infarction (AMI) has so far remained uncertain. METHODS: We analyzed data from the National Health Insurance Research Database (NHIRD), a...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Szu-Heng, Chen, Dong-Yi, Lin, Yu-Sheng, Mao, Chun-Tai, Tsai, Ming-Lung, Hsieh, Ming-Jer, Chou, Chung-Chuan, Wen, Ming-Shien, Wang, Chun-Chieh, Hsieh, I-Chang, Hung, Kuo-Chun, Chen, Tien-Hsing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2015
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4482692/
https://www.ncbi.nlm.nih.gov/pubmed/26115092
http://dx.doi.org/10.1371/journal.pone.0131122

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4482692/
https://www.ncbi.nlm.nih.gov/pubmed/26115092
http://dx.doi.org/10.1371/journal.pone.0131122

Ejemplares similares